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The goal of antiviral therapy for patients with chronic hepa-
titis C virus (HCV) infection is to attain a sustained virologic 
response (SVR), which is defined as undetectable serum 
HCV-RNA levels at 6 months after the cessation of treatment. 
Major improvements in antiviral therapy for chronic hepatitis 
C have occurred in the past decade. The addition of ribavirin 
to interferon-alfa therapy and the introduction of pegylated 
interferon (PEG-IFN) have substantially improved SVR rates 
in patients with chronic hepatitis C. The optimization of HCV 
therapy with PEG-IFN and ribavirin continues to evolve. Stud-
ies are ongoing that use viral kinetics to tailor therapy to an 
individual’s antiviral response and determine the ideal length 
of treatment to maximize the chance of SVR. Improved SVR 
can be achieved with new speciﬁ  c inhibitors that target the 
HCV NS3/4A protease and the NS5B polymerase. Several 
long-term follow-up studies have shown that SVR, when 
achieved, is associated with a very low risk of virologic re-
lapse. Furthermore, antiviral therapy can reduce the morbid-
ity and mortality rates associated with chronic hepatitis C by 
reducing ﬁ  brosis progression, the incidence of cirrhosis, and 
hepatocellular carcinoma. (Gut Liver 2011;5:117-132)
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INTRODUCTION
Hepatitis C virus (HCV) infects 170 million people worldwide.
1 
It causes severe liver disease, ranging from chronic hepatitis to 
cirrhosis and even hepatocellular carcinoma.
2 HCV-related liver 
diseases are responsible for 12,000 deaths annually in the Unit-
ed States. In contrast to most other viral infections, the hallmark 
of HCV viral infection is that most patients develop chronic in-
fection after viral exposure.
3 Unfortunately, no effective vaccine 
is available for HCV. The current treatment for chronic HCV 
infection is the combination of peginterferon (IFN)-α and a 
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nucleoside analogue, ribavirin.
4 This article reviews our current 
understanding of chronic hepatitis C infection.
EPIDEMIOLOGY 
HCV is an RNA virus known to infect humans and chim-
panzees, causing a similar disease in these 2 species. HCV is 
the most common cause of transfusion-related hepatitis and is 
one of the leading causes of end-stage liver disease requiring 
liver transplantation in the United States. HCV is transmitted 
most efficiently by parenteral means, particularly with large or 
repeated exposure to infected blood products, upon transplanta-
tion of infected tissue or organ grafts, and between intravenous 
drug users (IVDU). Less frequently, HCV can be transmitted by 
mucosal exposure to blood or serum-derived fluids through 
perinatal or sexual means.
5 
In 2004, the Global Burden of Hepatitis C Working Group, a 
consultant to the World Health Organization (WHO), estimated 
the global prevalence of HCV to be slightly lower than 2.2%, or 
130 million individuals. The lowest HCV prevalence, between 
0.01% and 0.1%, is in the United Kingdom and Scandinavia, 
while the highest prevalence, between 15% and 20%, is in 
Egypt (Fig. 1).
6 Hepatitis C is estimated to be the cause of 27% 
of cirrhosis and 25% of hepatocellular carcinoma (HCC) cases 
worldwide.
7
Prior to the implementation of universal screening of blood 
donors in the United States in 1992, the predominant mode of 
HCV transmission was exposure to infected blood and blood 
products. At present, IVDU and high-risk sexual exposures ac-
count for most HCV transmission.
6 Enhanced screening of blood 
products has led to a decline in the estimated incidence of acute 
hepatitis C from 180,000 in the mid-1980s to an estimated 
19,000 in 2006. HCV is estimated to cause 8,000 to 10,000 
deaths per year related to liver complications and HCC.
6
The WHO Western Pacific region has an estimated HCV 
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prevalence of 3.9%, or 62.2 million people. Approximately 3.2% 
of China’s population, or 38 million individuals, were found to 
have HCV in a national epidemiologic survey performed be-
tween 1992 and 1995. The primary means of transmission in 
China is IVDU, and HCV incidence in the injection drug user 
(IDU) cohort is as high as 3.6 cases per 100 person-years.
8 In Ja-
pan, the estimated HCV prevalence is 2%, or 2 million people.
9 
The prevalence is directly proportional to age, with the highest 
rate of 7% seen in individuals older than 70 years.
10 Modes of 
transmission include blood transfusions, IDU, and unsafe needle 
use in medical practice prior to 1980. Hepatitis C is the major 
etiological factor for HCC in Japan, where HBV is not endemic.
11
GENOTYPES 
There are 6 HCV genotypes (genotypes 1 to 6), many sub-
types (a, b, c, etc.), and approximately 100 different strains (1, 
2, 3, and so forth) based on the sequence heterogeneity of the 
HCV genome (Fig. 2).
12 Genotypes 1 to 3 are widely distributed 
globally, with genotypes 1a and 1b accounting for 60% of in-
fections worldwide. Genotype 1a is predominantly located in 
northern Europe and North America, whereas genotype 1b is 
predominantly found in southern and eastern Europe and Ja-
pan. Genotype 2 is less common than genotype 1 and is found 
more frequently in Europe than in North America. Genotype 3 is 
endemic to South-East Asia, and genotype 4 is characteristic of 
the Middle East, Egypt, and central Africa. Genotype 5 is almost 
exclusively found in South Africa, and genotype 6 is primarily 
distributed in Asia.
5,13-15
The impact of the viral genotype on the pathogenesis of liver 
disease remains a subject of controversy, but the influence of 
the genotype on the response to interferon-based therapy is 
established. Genotype 1 is generally associated with a poorer 
response to therapy, whereas genotypes 2 and 3 have more fa-
Fig. 1. Geographic distribution of 
hepatitis C infection worldwide, 
2007 (Data from International 
Travel and Health [Internet]. Geneva: 
World Health Organization; 2007 
[cited 2009 Mar 11]. Available from: 
http://www.who.int/ith/maps/hepati-
tisc2007.jpg).
Fig. 2. Hepatitis C virus (HCV) se-
quences have been classified into six 
major genotypes with approximately 
65% sequence identity. Within each 
genotype, sequences are further 
classified into subtypes with 78% 
sequence identity. Different isolates 
within the same subtype share 91% 
to 99% sequence identity. Within 
a host, HCV particles circulate as a 
population of very closely related, 
but not identical, variants referred 
to as quasispecies. Genotypes are 
denoted by numbers (1-6), and sub-
genotypes are denoted by lower case 
letters (Adapted from Fishman SL, et 
al. Infect Genet Evol 2009;9:1158-
1167).
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vorable responses. Genotype 4 seems to have an intermediate 
response.
15,16
VIROLOGY OF HEPATITIS C
HCV was first isolated in 1989.
17 It is a plus-stranded RNA vi-
rus with a genome size of 9.6 kb (Fig. 3).
1 The virus is classified 
as the distinct genus Hepacivirus in the family Flaviviridae.
18 
HCV replicates through a negative-strand RNA intermediate 
without evidence of DNA formation. Although viral RNA has 
been detected in the serum, spleen, and lymph nodes of infected 
patients, most in vivo and in vitro evidence supports the notion 
that HCV is a hepatotropic virus and that viral RNA replicates 
exclusively in human hepatocytes.
HCV encodes a single polyprotein of 3011 amino acids. 
Translation occurs through cap-independent and internal ribo-
some entry site-mediated mechanisms. The HCV internal ribo-
some entry site translation system requires the formation of a 
protein complex composed primarily of eukaryotic initiation 
factors 2 and 3.
19 This protein is subsequently processed into at 
least 10 functional proteins to support viral replication and pro-
duction.
A host signal peptidase is responsible for cleavage between C/
E1, E1/E2, E2/p7, and p7/NS2. Viral NS2, however, is respon-
sible for cleavage of NS2/3, and the NS3 protease is responsible 
for downstream protein processing.
20
The HCV core protein is a highly conserved viral capsid pro-
tein. In addition to its role in viral particle assembly, the core 
protein seems to exert multiple biologic functions on host cells, 
including gene transcriptional regulation,
21 apoptosis,
22,23 altera-
tion of IFN signaling,
24,25 cell transformation,
26,27 and interfer-
ence with lipid metabolism.
28 Many of these biologic effects of 
the core protein are thought to provide a survival advantage to 
the virus. 
The E1/E2 proteins are glycoproteins on the viral surface. 
These envelope proteins have attracted great interest because of 
their potential use in the development of an HCV vaccine.
29,30 
The E2 region is known to be hypervariable, however, which 
creates significant problems for the generation of effective neu-
tralizing antibodies. Recent experiments have demonstrated that 
E1/E2 proteins can form pseudoviral particles and that these 
particles are capable of eliciting antibody responses.
30-32 Inter-
estingly, it has also been reported that E2 can interact with the 
cellular protein PKR, a key signaling molecule in IFN-induced 
antiviral pathways.
33
The p7 protein is located between the structural and non-
structural proteins. This protein is embedded in the cellular 
membrane and functions as an ion channel. In a chimpanzee 
study, a virus with p7 mutations could not establish infection,
34 
indicating the essential role of this protein in the viral life cycle.
The viral NS2 protein is a serine protease responsible for the 
cleavage of NS2/3 and is an integral membrane protein. NS2 
can be phosphorylated by protein kinase CK2 and is involved in 
the modulation of cell apoptosis and transcription.
35 NS3/4A is 
responsible for most of the nonstructural protein processing. Re-
cently, NS3/4A was implicated in the modulation of host cellu-
lar functions. It was reported that HCV NS3 promoted caspase-
8-mediated apoptosis.
36 Interestingly, NS3/4 has been shown 
to interfere with the host innate immune system.
37,38 NS5A is a 
membrane-associated protein. It has a structural basis for inter-
acting with other proteins and viral RNAs.
39-41 NS5A is phos-
phorylated by cellular serine kinases, including MEK1, MKK6, 
AKT, p70S6K, and cAMP-dependent protein kinase A-a.
42-46 
In addition, NS5A appears to have the capacity to modulate 
multiple cellular functions, including cell transformation, tran-
scriptional regulation, and apoptosis. NS5A also interacts with 
other cellular factors to result in the suppression of IFN-induced 
antiviral efficacy.
47
NS5B is an RNA-dependent RNA polymerase responsible for 
viral RNA replication. The protein’s structure bears the typical 
‘‘right hand’’ polymerase domain.
48-50 The precise molecular pro-
cess of NS5B-mediated RNA replication remains to be defined, 
but replication complexes composed of multiple proteins appear 
to be involved.
51,52 Interestingly, a cellular replication cofactor, 
cyclophilin A, can enhance the RNA binding activity of NS5B, 
and cyclosporine exhibits anti-HCV activity through this mech-
anism.
53 
Although the molecular details underlying the entry of 
HCV into the host cell are unknown, CD81 seems to be a key 
receptor component mediating viral entry.
54,55 CD81 alone is 
not sufficient to convert nonpermissive cells to allow HCV 
entry, however, as demonstrated in cell culture and in CD81-
transgenic mice; such animals expressing human CD81 were 
not susceptible to HCV infection.
56,57 It is believed that other co-
factors in association with CD81 act to coordinate the entry of 
HCV into the host cells.
58 One viral protein that is likely essen-
Fig. 3. Genomic structure of hepatitis C virus (HCV). HCV is a plus-stranded RNA virus. The total viral protein is 3011 amino acids (aa) in length. 
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tial for host cell binding is E2, which has been demonstrated to 
bind CD81 both in vitro and in vivo.
59 Other potential receptors 
include low-density lipoprotein, negatively charged glycosami-
noglycans, and human scavenger receptor class B type 1.
60,61 An 
additional host cell molecule that was recently identified to be 
important for HCV entry is the tight junction protein Claudin-1 
(CLDN1). The expression of CLDN1 in several nonpermissive 
cell lines allowed viral entry, and siRNA silencing of CLDN1 
expression in permissive hepatoma cells reduced HCV infection 
and mutagenesis. Furthermore, antibody blocking studies with 
tagged versions of CLDN1 demonstrated that the first extracel-
lular loop of CLDN1 (EC1) is an essential coreceptor during one 
or more stages of the HCV entry process.
62 Recent studies have 
also identified occludin (OCLN), an integral tight junction (TJ) 
protein, as another key factor for HCV entry.
63 
The hallmark of HCV infection is the establishment of per-
sistent viral infection. The mechanisms underlying this remain 
unclear. Many lines of evidence appear to support the idea that 
HCV infection is noncytopathic. Several studies, including his-
tologic examination of liver biopsies, have shown that many 
HCV carriers have high titer virus expression and normal liver 
enzyme levels but little or no liver damage.
64-68 The course of 
varying degrees of hepatitis, whether to resolution or chronic 
infection, seems to be controlled at the level of the host immune 
response to virus-infected hepatocytes. It must be noted, how-
ever, that the majority of the data examining the relationship 
between host immune response and disease progression have 
been derived from patient populations with chronic infection, in 
which cases the virus and host hepatocytes had coevolved for 
some time. It remains to be determined whether HCV can exert 
cytopathic effects on naive hepatocytes during the initial viral 
exposure. Understanding how HCV establishes persistent infec-
tion is crucial for future strategies to control this disease. 
Over the past decade, many mechanisms by which HCV may 
establish chronicity have been proposed.
3,69 These mechanisms 
include virus-encoded anti-host immune strategies, virus-in-
duced immunologic tolerance, viral escape mutations, molecular 
mimicry, and decreased effectiveness of antiviral cytokines. In 
recent years, experimental evidence has suggested that virus-
encoded, anti-host strategies play an essential role in the estab-
lishment of persistent viral infection (Fig. 4).
70 All mammalian 
nucleated cells have an innate capacity to respond to a viral 
infection through the production of type I IFNs or other inflam-
matory cytokines.
71-73 This defense system has been extensively 
studied, leading to a wealth of knowledge on the molecular ba-
sis of this innate immune system.
FACTORS IMPACTING TREATMENT RESPONSE
The viral factors that have been demonstrated to play a role 
in the response to IFN-based therapy include genotype and vi-
ral load. Patients with low baseline viremia (below 400,000 IU/
Fig. 4. Molecular processes that signal the host response to hepatitis C virus infection (Adapted from Gale M Jr, et al. Nature 2005;436:939-945).
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mL) are more likely to respond to therapy than patients with 
high baseline viremia.
74 Numerous host factors can influence 
treatment outcomes, including age, sex, race, weight, liver fi-
brosis, steatosis, and insulin resistance. Unfortunately, most 
host factors cannot be altered (age, sex, race, fibrosis), and those 
that can be altered may not be associated with an improved 
sustained viral response (SVR). A recently uncovered example 
of the influence of host factors on SVR is insulin resistance, the 
presence of which prior to treatment leads to a dramatic reduc-
tion in SVR rates.
75 Insulin resistance seems to be involved in 
decreased sensitivity to interferon and could block intracellular 
interferon signaling. Recently, a new and powerful host variable 
was found using genome-wide association studies. A genetic 
polymorphism near the IL-28B gene region, which encodes for 
interferon lambda, has been closely linked to the IFN response. 
Patients with the CC allele have a very high SVR compared to 
those with a T-containing allele (Fig. 5).
76 The IL-28B polymor-
phism influences virologic responses and relapse rates and has 
become the most powerful pretreatment predictor of SVR.
77 
In fact, with the era of direct antiviral therapies close at hand, 
testing for this polymorphism will be critical in determining 
who should be treated immediately and who should wait for 
improved treatment regimens. Patients who have the favorably 
responding CC IL-28B genotype have a high likelihood of at-
taining SVR and, in the absence of other concerns regarding 
their candidacy for therapy, should be considered candidates for 
standard PEG-IFN and RBV therapy. In contrast, patients with 
the non-CC IL-28B genotype, especially if other markers of poor 
response are present (e.g., high viral load, insulin resistance, and 
African American ancestry), are unlikely to achieve SVR and 
should consider waiting for improved response rates with direct 
antivirals.
78,79
TREATMENT CANDIDATES
Antiviral therapy for chronic hepatitis C is currently recom-
mended for patients who 1) are older than 18 years, 2) have 
positive findings for HCV antibodies and serum HCV RNA, 3) 
have liver biopsy findings consistent with a diagnosis of chronic 
hepatitis, although a biopsy is not essential, and 4) have no con-
traindications for treatment. PEG-IFN and RBV cannot be used 
in patients with decompensated cirrhosis, severe depression, or 
cardiopulmonary disease. 
DEFINITION OF VIRAL RESPONSE PATTERNS AND AS-
SOCIATED SVR 
The monitoring of on-treatment viral responses has become 
a vital aspect of treatment regimens and allows one to predict 
the treatment response, to consider therapy adjustments, and 
to develop stopping rules governing cessation of therapy. A 
clear relationship has been established between the time to viral 
negativity and SVR. Patients who initially achieve serum viral 
negativity by week 4 (RVR) or week 12 (cEVR) have 91% and 
60% to 72% SVR rates, respectively, following 48 weeks of 
therapy. Patients who decrease their viral loads by 2 logs fol-
lowing 12 weeks of treatment and who achieve viral negativity 
by week 24 are referred to as slow responders and have much 
lower rates of SVR (35% to 45%). Patients who do not achieve 
a 2-log reduction by week 12 or viral negativity by week 24 
have only a 2% chance of achieving SVR with therapy, and 
treatments are therefore typically stopped.
80 On-treatment viral 
response definitions related to week-4, -12, and -24 HCV RNA 
determinations and their relationships to SVR are shown below 
(Figs 6 and 7): 
• Rapid virological response (RVR): HCV RNA negative (<50 
IU/mL) after 4 weeks of therapy
Fig. 5. Percentage of sustained virologic response (SVR) by 
rs12979860 genotypes (Adapted from Ge D, et al. Nature 2009; 
461:399-401).
76
Fig. 6. Graphic display of virological responses (Adapted from AAS-
LD Practice Guideline: Diagnosis, Management, and Treatment of 
Hepatitis C. An Update).
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• Early virological response (EVR): viral response at 12 weeks, 
subdivided into:
- Partial EVR (pEVR): HCV RNA >2-log drop, but still detect-
able at week 12
- Complete EVR (cEVR): no RVR, but HCV RNA <50 IU/mL 
at week 12
• Nonresponse: persistent or inadequate reduction in HCV 
RNA during therapy, subdivided into:
- Null response: either <1-log decrease in HCV RNA at week 
4 or <2-log decrease in HCV RNA by week 12
- Partial response: greater than a 2-log decrease by week 12, 
but continued viral positivity at week 24
Partial and null responses are associated with <5% likelihood 
for SVR and have been accepted as a general stopping rule. 
TREATMENT 
1. Goals of treatment
The primary goal of chronic HCV treatment is a SVR, which 
is defined as undetectable serum HCV RNA levels 6 months 
after treatment cessation. For patients to achieve this goal, 
however, three independent milestones must be sequentially 
achieved. The first of these is that the patient must achieve a 
virologic response and have undetectable HCV RNA levels dur-
ing treatment. It is fairly evident but rarely stated that patients 
without a virologic response cannot possibly achieve SVR. The 
second step is that the patient must maintain this response by 
maintaining undetectable HCV RNA levels throughout the dura-
tion of therapy. With few exceptions, patients who experience 
breakthrough and become HCV RNA-positive during treatment 
do not achieve SVR. The final step for SVR is that the patient 
must not relapse following treatment. 
2. Response-guided therapy
The current effective treatment for chronic HCV infection is 
a combination of peginterferon and ribavirin.
81,82 The term EVR 
refers to a 2-log decline in HCV RNA levels from the pretreat-
ment baseline or undetectable HCV RNA levels within 12 weeks 
of treatment initiation.
81,83,84 Approximately 80% of patients 
with genotype 1 and virtually all patients with genotypes 2 or 
3 achieve an EVR.
80,81,83-86 Patients without EVR rarely if ever 
achieve SVR.
80,81,83,84,86 These patients are referred to as having a 
null response.
87 At the Second National Institutes of Health Con-
sensus Development Conference on the Management of HCV, 
it was recommended that all patients infected with genotype 1 
should undergo HCV RNA testing at baseline and at week 12.
83,84 
Patients without EVR (a null response) should cease treatment 
because they cannot achieve SVR. It was further recommended 
that all genotype 1-infected patients showing EVR should con-
tinue treatment for 48 weeks and that all patients infected with 
genotypes 2 and 3 should simply be treated for 24 weeks.
81,83,84
Defining the time when HCV RNA first becomes undetect-
able in the patient is critically important in the management 
of HCV treatment because this measurement is directly related 
to the likelihood of SVR.
80 Patients in whom HCV RNA is un-
detectable within 4 weeks of initiating treatment are referred 
to as having a RVR. Approximately 15% of patients infected 
with genotype 1 and 66% of patients infected with genotypes 
2 and 3 achieve RVR.
80,85 These patients are exquisitely sensi-
tive to treatment; they achieve SVR at a rate of 90% regardless 
of their genotype and the type of therapy they receive.
80,85 In a 
retrospective analysis of a large clinical trial database, patients 
infected with genotype 1 and showing RVR had a 90% likeli-
hood of achieving SVR whether treated with peginterferon and 
full-dose ribavirin, a lower dose of ribavirin, standard interferon 
Fig. 7. Rates of viral clearance predict sustained virologic response in 
patients with PEG-RBV treatment (Adapted from Ferenci P, et al. J 
Hepatol 2005;43:425-433).
80
Fig. 8. End-of-treatment and sustained virological responses in 
patients with a rapid virological response (undetectable HCV RNA) 
at week 4. The number of patients in each group is presented at 
the base of each bar (Adapted from Jensen DM, et al. Hepatology 
2006;43:954-960).
88
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and ribavirin, or even peginterferon monotherapy.
80,88 Shorten-
ing the duration of therapy from 48 to 24 weeks also appeared 
to be effective in achieving high rates of SVR in genotype 1-in-
fected patients showing RVR (Fig. 8).
88 These observations have 
significant implications for peginterferon and ribavirin dosing. 
Because patients with RVR are highly responsive to treatment, 
the primary response to adverse events in these patients should 
include reducing the dose of peginterferon or ribavirin and not 
adding growth factors or other adjuvant therapies.
The later during treatment that a patient’s HCV RNA becomes 
undetectable, the lower the likelihood of SVR.
80 Patients infected 
with genotype 1 for whom the HCV RNA becomes undetectable 
between treatment weeks 4 and 12 have an SVR rate of ap-
proximately 66%, but those for whom the HCV RNA becomes 
undetectable between weeks 12 and 24 have an SVR rate of 
only 45%. The low SVR rate in slow responders occurs because 
of a higher rate of relapse. Genotype 1-infected patients with 
undetectable HCV RNA levels between weeks 12 and 24 have 
been referred to as ‘‘slow to respond,’’ and recent studies have 
demonstrated that prolonging the duration of treatment in these 
patients from 48 to 72 weeks can significantly reduce relapse 
rates.
89,90 This treatment schedule would obviously enhance the 
likelihood of SVR. Patients infected with genotypes 2 and 3 in 
whom HCV RNA is not undetectable after week 4 have an SVR 
rate of only 49%,
85 and a recent retrospective analysis suggested 
that prolonging treatment in these patients could also reduce 
relapse.
3. Breakthrough and relapse
Two additional patterns of virologic response are important 
to recognize: breakthrough and relapse. Breakthrough is char-
acterized by initially undetectable serum HCV RNA levels dur-
ing treatment and a reappearance of serum HCV RNA despite 
ongoing treatment. Patients with relapse achieve and maintain 
undetectable HCV RNA serum levels throughout treatment but 
experience a reappearance of serum HCV RNA after treatment 
is discontinued. Common reasons for breakthrough and relapse 
include premature termination or temporary interruption of pe-
ginterferon or ribavirin.
91
4. Dose regimens
The recommended starting doses for the two peginterferons 
aim to achieve the highest overall SVR rates. These doses were 
derived by balancing response and discontinuation rates. Be-
cause most patients respond to the current starting dosages of 
peginterferon (180 mg/wk for peginterferon alfa-2a and 1.5 mg/
kg/wk for peginterferon alfa-2b), it is not appropriate to initiate 
treatment with higher doses of these medications. The major 
limitation to using higher doses of interferon or peginterferon is 
the incidence of adverse events, which increases with increasing 
dose and causes patients to discontinue treatment.
92 In contrast, 
it is reasonable to consider escalating the dose of peginterferon 
or to switch to high doses of daily interferon in patients with 
suboptimal responses who could tolerate such treatment strate-
gies.
The treatment of chronic HCV with peginterferon and riba-
virin is associated with numerous adverse events.
81,82 The most 
common of these can be classified as systemic flu-like symp-
toms, psychiatric manifestations, autoimmune reactions, and 
hematologic toxicities. Although adverse events can be suc-
cessfully managed in many cases, approximately 20% to 40% 
of patients require that the dose of peginterferon or ribavirin be 
reduced or temporarily interrupted. In 10% to 14% of patients, 
adverse events are so severe that treatment must be discontin-
ued.
81,82 Higher doses of peginterferon and ribavirin have been 
associated with a greater incidence of adverse events.
92-96
The need to alter peginterferon or ribavirin dosing in response 
to adverse events may have a negative impact on SVR. Two 
studies have clearly demonstrated that when the dose of pegin-
terferon is reduced to less than 80% of the initial dose within 
the first 12 to 20 weeks of treatment, the ability of the patient 
to achieve EVR and to attain undetectable HCV RNA levels is 
significantly impaired.
86,97 This is consistent with observations 
that achieving a virologic response depends highly on the dose 
of interferon
98 or peginterferon
92-94 and depends far less on the 
ribavirin dose.
95,99 Because achieving a virologic response is the 
first essential milestone in achieving SVR, any reduction in the 
response of HCV RNA levels has a negative impact on the SVR 
rate.
The impacts of independent reductions in peginterferon or 
ribavirin doses were examined in patients with prior nonre-
sponse to interferon (with or without ribavirin) undergoing 
retreatment with peginterferon and ribavirin in the Hepatitis 
C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) 
clinical trial.
97 This study included more than 900 patients in-
fected with genotype 1, making it the largest and most compre-
hensive analysis of dose reduction performed to date. Reducing 
the total cumulative dose of peginterferon to less than 80% of 
the initial dose led to a decline in virologic response and SVR. 
In contrast, reducing the dose of ribavirin had no impact on 
virologic response or SVR as long as patients remained on full-
dose peginterferon and did not have interrupted or prematurely 
terminated ribavarin dosing. 
Several studies have shown that the reappearance of HCV 
RNA after SVR is extremely rare (less than 1%),
100-102 but close 
follow-up is recommended.
103 
5. Treatment of hepatitis C in special situations
1) Acute hepatitis C 
The identification of acute HCV infection represents a unique 
window of opportunity for achieving high rates of viral clear-
ance. An observation period of 12 weeks is recommended for 
patients with symptomatic hepatitis to allow for the spontane-
ous viral clearance that can occur at high rates in this subgroup. 124  Gut and Liver, Vol. 5, No. 2, June 2011
Asymptomatic patients may be treated immediately, as they are 
less likely to undergo spontaneous clearance. Treatment dura-
tions can vary from 24 to 48 weeks, but results from a recent 
analysis of 12-week treatments are encouraging, especially in 
those who achieve RVR. Variables associated with improved 
response rates include female gender, the presence of symptom-
atic hepatitis, younger age, non-genotype 1 infection, and RVR. 
Based on the current data, a management algorithm is proposed 
(Fig. 9)
104 to guide the clinician in making treatment decisions. 
Of course, adherence to the prescribed therapy is extremely im-
portant in ensuring successful outcomes. 
2) HIV/HCV coinfection 
Because of their shared transmission routes, the prevalence of 
HCV and HIV coinfection ranges from 10% to 40%, or even as 
high as 80%, in highly exposed populations.
105-107 Current esti-
mates suggest that nearly 10 million individuals worldwide and 
300,000 in the United States are coinfected. Because decreased 
mortality from opportunistic infections has been achieved with 
the use of highly active antiretroviral therapy (HAART), liver 
disease has emerged as a serious cause of morbidity and mortal-
ity among HIV-infected patients.
108 HIV infection leads to in-
creased HCV-RNA levels and faster progression of liver fibrosis. 
These complications consequently lead to cirrhosis, liver failure, 
and HCC.
109,110 
Several studies with pegylated IFN alfa and ribavirin have 
been reported.
111-114 Similar to studies of patients infected with 
HCV alone, these trials show improved virologic response rates 
with the use of pegylated IFN alfa plus ribavirin compared with 
unmodified IFN alfa plus ribavirin. These studies also show 
lower response rates for patients infected with genotype 1. In 
addition, the early virologic response (undetectable HCV RNA 
level or >2-log reduction in HCV RNA levels by week 12) also 
seemed to be a helpful predictor. 
As with monoinfected patients, an important issue in HCV 
treatment is determining the appropriate time to initiate treat-
ment in patients coinfected with HIV/HCV. When patients 
present with decompensated liver disease, complications of 
Fig. 9. Treatment algorithm for the management of acute hepatitis C (Adapted from Maheshwari A, et al. Clin Liver Dis 2010;14:169-176).
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HCV therapy make treatment unsafe. Effective screening and 
early intervention are therefore critical. Treatment must also be 
planned in concert with a patient’s HIV physician to ensure that 
the patient is at a stable point in his or her HIV antiretroviral 
regimen. In recent HIV/HCV studies, more than 80% of patients 
were receiving antiretroviral therapy, and HIV RNA was unde-
tectable in most of these patients. In addition, mean CD4 counts 
were greater than 400×10
6/L in all trials. Considering these posi-
tive patient characteristics, these represented optimal HIV/HCV 
populations, but poor tolerance and adherence still emerged in 
these favorable patient groups.
111-114 
The risk-benefit analysis of HCV treatment in patients with 
HIV/HCV remains a matter of debate, and the safety and toler-
ability of therapy are therefore important concerns. HAART can 
be associated with hepatotoxicity ranging from elevated ALT 
levels to hepatic decompensation.
115,116 Symptomatic mitochon-
drial toxicity (acute pancreatitis, lactic acidosis, or hyperlac-
tatemia) has been reported in HIV-infected patients receiving 
HAART and ribavirin, and it is increased when the regimen 
includes didanosine.
113 Chung and colleagues
111 reported a clini-
cally significant pancreatitis in only one patient but a lipase 
elevation in 18 subjects. Another important issue with respect 
to HIV/HCV comorbidity relates to the additive side effects ob-
served during HCV and HIV therapies. Anemia, thrombocytope-
nia, and neutropenia are common with peginterferon alfa and 
ribavirin treatments and may be exacerbated in the setting of 
antiretroviral therapy. Torriani et al.
112 reported 37 cases (13%) 
of neutropenia (<500/mm
3) in recipients receiving peginterferon 
alfa-2a plus placebo and 31 cases (11%) in recipients receiving 
peginterferon alfa-2a plus ribavirin; five subjects withdrew from 
treatment because of severe anemia. If these side effects lead to 
dose reductions of pegylated IFN and ribavirin, treatment with 
growth factors or even the selection of different antiretroviral 
agents may need to be considered.
3) Renal failure 
Chronic HCV infection is a significant cause of morbidity and 
mortality in patients with end-stage renal disease (ESRD). The 
prevalence of anti-HCV antibodies in patients with ESRD in the 
United States is significantly higher than that in the general 
population and is estimated to be between 8% and 10%.
117,118 
The natural history of HCV in patients who have ESRD, how-
ever, remains controversial. Studies of HCV infection in ESRD 
patients report mild to moderate disease, ALT levels that are 
usually within the normal range, and low proportions of pa-
tients with advanced fibrosis or cirrhosis.
119,120 Mortality rates of 
patients with both HCV and ESRD, however, appear to be higher 
than rates for either ESRD or HCV alone. Stehman-Breen et al.
121 
reported that patients with HCV and ESRD are at an increased 
risk of death compared to patients with ESRD but not HCV, with 
an adjusted relative risk of mortality of 1.78 (95% confidence 
interval [CI], 1.01 to 3.14; p=0.045). A prospective cohort study 
followed 1,470 Japanese patients receiving hemodialysis for 
6 years.
122 The mortality rate was higher in patients with HCV 
infection than in those without HCV infection (33.0% vs 23.2%, 
p<0.01). HCC and cirrhosis were more frequent in patients with 
HCV infection. 
Because of the relatively high rate of comorbidity between 
these two diseases, there is significant a motivation to consider 
the treatment of patients with both ESRD and HCV infection. 
This impetus is heightened if kidney transplantation is being 
considered. HCV infection is associated with decreased survival 
of the patient and the graft following kidney transplanta-
tion.
123,124 Fabrizi et al.
125 examined the impact of the develop-
ment of posttransplantation diabetes mellitus on patient and 
graft survival following kidney transplantation. In a systematic 
review of 10 studies, they found an incidence of posttransplan-
tation diabetes mellitus of between 7.9% and 50%. They also 
reported that this complication was more common in patients 
with HCV infections (odds ratio, 3.97; 95% CI, 1.83 to 8.61).
125 
Initial studies of HCV following kidney transplantation revealed 
that unmodified IFN alfa monotherapy improved ALT levels 
and led to a loss of HCV RNA but no predictable SVR.
126-128 
Acute cellular rejection, renal failure, and even graft loss were 
increased in patients treated with IFN alfa, leading to concerns 
regarding HCV treatment following kidney transplantation. As a 
result, recent attention has focused on treatment prior to kidney 
transplantation. 
Many studies have been published on the use of IFN therapy 
for the treatment of HCV infection in patients with ESRD. Russo 
et al.
129 conducted a systematic review of literature published 
between 1986 and 2001 and included data from 11 studies. In 
213 patients treated with unmodified IFN alfa, SVR was 33% 
overall (95% CI, 21% to 51%) and was 26% for patients infected 
with genotype 1 (95% CI, 15% to 37%). Another meta-analysis 
by Meyers et al.
130 included 17 studies. The overall SVR was 
40% in patients receiving unmodified IFN alfa monotherapy. 
These pooled response rates with unmodified IFN alfa mono-
therapy are substantially higher than those seen in patients 
without renal disease. The most salient feature of these studies 
is the high rate of serious adverse events. Early discontinuation 
rates averaged at 26%. Dose modification rates were high, and 
adverse events were severe and included pulmonary edema, ce-
rebral hemorrhage, cardiomyopathy, lymphoma, and acute pan-
creatitis. Several studies of patients with comorbid ESRD and 
HCV used combination therapy with unmodified IFN alfa and 
ribavirin. Ribavirin is cleared by the kidney and causes a dose-
related, potentially severe hemolysis.
130
IMPACT OF TREATMENT
Durable loss of detectable virus from the serum is observed 
in almost all patients who achieve SVR (i.e., >99%). Moreover, 
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or extrahepatic sites following SVR.
131 Most studies have also 
demonstrated histologic improvement, with up to 62% of pa-
tients achieving normal histological results after demonstrating 
SVR
132 and a similar percentage showing a regression of fibrosis 
of up to 0.8 Metavir units per year.
133 In addition to histologic 
improvement, several studies report that patients with SVR 
have a reduced risk of long-term HCV complications. Evidence 
overwhelmingly shows that achieving SVR increases the pos-
sibility of positive outcomes, including a reduced risk of HCC 
and decompensation and improved survival.
134-136 In addition, a 
recent study by Bruno shows that achievement of SVR prevents 
the development of esophageal varices (0% in SVR vs 32% in 
untreated subjects over 12 years of follow-up).
134 These studies 
present a clear picture of the striking reduction in the risk of 
complications of liver disease following SVR. 
NEW TREATMENTS FOR CHRONIC HEPATITIS C
The depth of our understanding of the HCV life cycle has 
significantly expanded over the previous decade and has led 
to multiple new anti-HCV therapies now under investigation. 
Initially, such oral specifically targeted antiviral therapies for 
hepatitis C (STAT-C) drugs will most likely be added to cur-
rent PEG-RBV therapies and could lead to improved response 
rates and shorter therapy durations. Improved SVR rates could 
be achieved with new HCV-specific inhibitors that target the 
NS3/4A and NS5B polymerases. Recent trials reported SVR rates 
on the order of 61% to 68% and 67% to 75% following com-
bination treatments of standard of care (SOC) and the protease 
inhibitors telaprevir (Fig. 10)
79 and boceprevir,
137 respectively, in 
patients with HCV genotype 1 infection. Future trials will need 
to evaluate the use of ‘‘cocktails’’ of oral agents to determine 
whether viral resistance can be minimized with HCV as it has 
been with HIV and HBV. Resistance could be avoided by either 
combining two or more specific inhibitors with non-verlapping 
resistance profiles, such as protease inhibitors with nucleoside 
and/or non-nucleoside inhibitors, or combining HCV-specific 
inhibitors with non-HCV-specific inhibitors, such as cyclophilin 
inhibitors. Although these therapy options are not yet available, 
we now have the ability to adopt improved strategies to maxi-
mize response rates with available therapies and to tailor treat-
ment durations based on individual viral kinetic responses.
138 
SCREENING FOR HEPATOCELLULAR CARCINOMA
The association of chronic hepatitis C with the development 
of hepatocellular carcinoma (HCC) is well documented. Most 
studies describing this association are retrospective case-control 
studies, retrospective cohort studies, or prospective cohort stud-
ies. Studies in Italy have described the incidence of hepatitis 
C cirrhosis to be 3.7 in 100,000 per year,
139 the relative risk of 
HCC in patients positive for anti-HCV antibodies to be 21.3 
compared with controls,
140 and the odds ratio of developing 
HCC if positive for anti-HCV to be 69.
140 In two studies, 71% of 
HCC patients were positive for the anti-HCV.
140,141 A study in the 
United States showed a relative risk of 4.8 and an attributable 
risk of 47% for HCV patients to develop HCC.
142 One Japanese 
study showed a relative risk of 53 of developing HCC if pa-
tients were anti-HCV-positive. In this study, the prevalence of 
anti-HCV as a risk factor for HCC was 78%.
143 Studies in Italy, 
France, Germany, and other countries have reached similar 
conclusions.
144-146 A single large-scale, prospective, controlled 
cohort study showed that HCV infection conferred a 20-fold in-
creased risk for the development of HCC.
147 The high incidence 
of HCC in patients with chronic hepatitis C-related cirrhosis has 
led to the introduction of screening for HCC in this population. 
Patients with hepatitis C without cirrhosis are not required to 
undergo HCC screening. An appropriate guiding principle is that 
the best available screening test should be chosen and applied 
regularly. Combined use of AFP and ultrasonography increases 
detection rates. Guidelines issued by the American Association 
for Study of Liver Diseases
148 suggest a 6- to 12-month interval. 
Once an abnormal screening has been identified and patients 
enter into enhanced follow-up, the interval between evaluations 
should be shorter.
SUMMARY
1) The primary goal of treatment of chronic HCV is the at-
tainment of SVR, defined as undetectable serum HCV-RNA lev-
els at 6 months after treatment cessation. Once SVR is achieved, 
improved histological and clinical benefits follow (e.g., lower 
rates of decompensation, hepatocellular carcinoma, and mortal-
ity). 
2) The viral factors that influence the response to IFN-based 
therapy include genotype and viral load. The IL28B genotype, 
a powerful host factor in determining IFN responsiveness, will 
Fig. 10. Telaprevir increases sustained virologic response rates in 
patients with hepatitis C virus genotype 1 infection (Data from 
McHutchison JG, et al. N Engl J Med 2009;360:1827-1838).
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eventually be used to help stratify patients for treatment.
3) The evaluation of on-treatment viral response allows for 
individualized treatment durations. Patients who demonstrate 
RVR are particularly sensitive to treatment. Shortening the du-
ration of the therapy from 48 to only 24 weeks also seems to be 
effective in achieving high rates of SVR in genotype 1-infected 
patients who demonstrate RVR. Patients without EVR (a null re-
sponse) should cease treatment because they have little chance 
of achieving SVR. 
4) Improved rates of SVR can be achieved with new HCV-
specific inhibitors against the NS3/4A and NS5B polymerases. 
An expanded understanding of the host proteins that enable 
HCV replication will allow for the identification of additional 
targets, eventually permitting the design of IFN-sparing regi-
mens.
FUTURE DIRECTIONS
The addition of a protease inhibitor to a backbone of PEG/
ribavirin will emerge as the new standard of care for treatment-
naïve patients with genotype 1 HCV or for patients with prior 
non-response or relapse to PEG/ribavirin treatment. Two direct-
acting antivirals (DAAs) (a protease inhibitor and a nucleoside 
polymerase inhibitor) could be combined for successful, short-
term treatments. It is not unreasonable to expect that sufficient 
agents will be available to permit such a combination within 
the next 5 to 10 years. We can anticipate the introduction of 
strategies that add a second agent to the PEG/ribavirin/protease 
inhibitor backbone, particularly in difficult-to-treat patients, al-
though the limits of tolerability are clearly being tested. Finally, 
the use of genetic testing for SNPs in the IL28B gene, which has 
been shown to have a powerful predictive value for SVR in pa-
tients treated with PEG/ribavirin, will also likely influence treat-
ment decisions. Genotype information will potentially permit 
abbreviated courses of therapy in those with a favorable geno-
type or will indicate a deferment of IFN-based therapy for those 
with the unfavorable IL28B genotype. The predictive power of 
IL28B testing, however, will require reconfiguration in the wake 
of new DAA-based therapy.
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